BioCentury
ARTICLE | Clinical News

Nebido regulatory update

December 7, 2009 8:00 AM UTC

FDA issued a complete response letter for an NDA from Endo for Aveed to treat male hypogonadism. The company said FDA requested information regarding serious adverse events, including post-injection a...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article